Ki-67

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

Retrieved on: 
Tuesday, April 9, 2024
Plasma, MRI, Neoplasm, Atossa, Ki-67, Associate, RECIST, Magnetic resonance imaging, Incidence, Patient, MD, Woman, AACR, Clinical trial, Therapy, Breast cancer, Safety, Division, Recurrence, Exemestane, Annual general meeting, Medical imaging

SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial.

Key Points: 
  • SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial.
  • Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
  • The data, which is being presented at the American Association for Cancer Research (AACR) Annual Meeting, is from the 40mg pharmacokinetic (PK) run-in cohort of the study.
  • At 28 days, six of the seven had Ki-67 levels below 10% and stayed on treatment for an additional five months.

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient

Retrieved on: 
Tuesday, March 19, 2024
Diagnosis, Growth, Ki-67, Neoadjuvant therapy, Mammography, Cancer, Expanded access, Woman, Neoplasm, Therapy, Breast cancer, CYP2D6, Safety, Axis, Osteoporosis, Hot, Recurrence, Tamoxifen, FDA, Enzyme inhibitor, PR, Pharmaceutical industry

Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Key Points: 
  • Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
  • Over five years of adjuvant treatment, her daily (Z)-endoxifen treatment has been well tolerated, and there were no vasomotor symptoms commonly associated with standard of care adjuvant pharmaceuticals.
  • She remains cancer-free today and we are grateful to have been able to help her with a difficult treatment problem.”
    Diagnosis.
  • Under the FDA Expanded Access IND program, the use of Atossa's proprietary (Z)-endoxifen is restricted to this patient only.

Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill

Retrieved on: 
Wednesday, August 23, 2023
Hair, Collagen, Stem cell factor, Face, Ki-67, Oxygen, Survival, Nail, Hair follicle, DHT, Multimedia, Signal, Hair loss, Neck, Scalp, GHK, Capillary, Plasma, FGF2, Peptide, Blood, Testosterone, Microcirculation, Biotin, Health, Exosome, Human, Melanocyte, SCF, Saliva, Wound healing, Cosmetics, Dietary supplement, Vaccine, Copper, Sulfur, Minoxidil

SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.

Key Points: 
  • SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.
  • HAIRNA Exosome Hair Fill is developed with Maypharm's exclusive technology for scalp rejuvenation and hair growth.
  • In addition to HAIRNA Exosome Hair Fill, Maypharm has launched such popular human stem cell products such as 2XSOME for face and neck.
  • Whether you are looking to improve your appearance or to regain self-confidence, HAIRNA Exosome Hair Fill is a solution that is hard to beat.

Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill

Retrieved on: 
Wednesday, August 23, 2023
Hair, Collagen, Stem cell factor, Face, Ki-67, Oxygen, Survival, Nail, Hair follicle, DHT, Signal, Hair loss, Neck, Scalp, GHK, Capillary, Plasma, FGF2, Peptide, Blood, Testosterone, Microcirculation, Biotin, Health, Exosome, Human, Melanocyte, SCF, Saliva, Wound healing, Cosmetics, Dietary supplement, Vaccine, Copper, Sulfur, Minoxidil

SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.

Key Points: 
  • SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.
  • HAIRNA Exosome Hair Fill is developed with Maypharm's exclusive technology for scalp rejuvenation and hair growth.
  • In addition to HAIRNA Exosome Hair Fill, Maypharm has launched such popular human stem cell products such as 2XSOME for face and neck.
  • Whether you are looking to improve your appearance or to regain self-confidence, HAIRNA Exosome Hair Fill is a solution that is hard to beat.

Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada

Retrieved on: 
Thursday, July 20, 2023
Exemestane, Ki-67, Goserelin, Woman, Atossa, SERM, Clinical trial, Patient, ESD, Therapy, Health Canada, Breast cancer, Pharmaceutical industry

SEATTLE, July 20, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that Health Canada has issued a “No Objection Letter” following the Company’s Clinical Trial Application for its Phase 2 EVANGELINE study.

Key Points: 
  • SEATTLE, July 20, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that Health Canada has issued a “No Objection Letter” following the Company’s Clinical Trial Application for its Phase 2 EVANGELINE study.
  • This means Atossa can open sites and enroll patients in their Phase 2 EVANGELINE study throughout Canada.
  • The study is expected to enroll approximately 175 patients at sites across the United States and Canada.
  • Once the dose is confirmed, we expect the pace of enrollment to increase as we activate additional sites in the United Sates and Canada.”

AI in Pathology Market worth $49 million | MarketsandMarkets

Retrieved on: 
Friday, July 14, 2023
ER, Human, Mayo Clinic, Partnership, KSR International Co. v. Teleflex Inc., Ki-67, Marie Cassidy, AP, Intelligence, Minerva Surgical, Inc. v. Hologic, Inc., Predictive analytics, Verily, HIV disease progression rates, Algorithm, Anomaly, HALO, Artificial intelligence, Knowledge, Clinical professor, AI, Corona Labs Inc., Education, PR, Breast cancer, Cryptocurrency, Medical device, Medical imaging, Pathology

The agreement helped to provide a fully interoperable solution between Indica Labs' HALO AP image management software platform and Lunit's suite of AI pathology products.

Key Points: 
  • The agreement helped to provide a fully interoperable solution between Indica Labs' HALO AP image management software platform and Lunit's suite of AI pathology products.
  • Through this partnership, the company aimed to bring the power of artificial intelligence to digital pathology.
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=86647266
    AI in Pathology Market Advantages:
    Improved Accuracy: AI algorithms can analyze large volumes of medical data with high precision and accuracy.
  • Cost Reduction: By increasing efficiency and accuracy, AI in pathology has the potential to reduce healthcare costs.

AI in Pathology Market worth $49 million | MarketsandMarkets

Retrieved on: 
Friday, July 14, 2023
ER, Human, Mayo Clinic, Partnership, KSR International Co. v. Teleflex Inc., Ki-67, Marie Cassidy, AP, Intelligence, Minerva Surgical, Inc. v. Hologic, Inc., Predictive analytics, Verily, HIV disease progression rates, Algorithm, Anomaly, HALO, Artificial intelligence, Knowledge, Clinical professor, AI, Corona Labs Inc., Education, PR, Breast cancer, Cryptocurrency, Medical device, Medical imaging, Pathology

The agreement helped to provide a fully interoperable solution between Indica Labs' HALO AP image management software platform and Lunit's suite of AI pathology products.

Key Points: 
  • The agreement helped to provide a fully interoperable solution between Indica Labs' HALO AP image management software platform and Lunit's suite of AI pathology products.
  • Through this partnership, the company aimed to bring the power of artificial intelligence to digital pathology.
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=86647266
    AI in Pathology Market Advantages:
    Improved Accuracy: AI algorithms can analyze large volumes of medical data with high precision and accuracy.
  • Cost Reduction: By increasing efficiency and accuracy, AI in pathology has the potential to reduce healthcare costs.

Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial

Retrieved on: 
Tuesday, March 21, 2023
Selective estrogen receptor modulator, FNIH, University, Axis, Exemestane, Ki-67, Neoplasm, University of California, San Francisco, Clinical trial, Goserelin, MBD, Cancer, Woman, Hypothalamic–pituitary–gonadal axis, EOP, Bangladesh Technical Education Board, Atossa, Biomarker, Incidence, SERM, Quantum Leap, Patient, Risk, SAN, Enzyme inhibitor, Disease, Growth, Mortality, ESD, Therapy, Recurrence, Regulation of tobacco by the U.S. Food and Drug Administration, Tamoxifen, Food, ER, Breast cancer, Pharmaceutical industry, Birth control

"Data from this trial will supplement data generated through our ongoing Phase 2 EVANGELINE trial, which is investigating (Z)-endoxifen as a neoadjuvant treatment for premenopausal women with ER+ / HER2- breast cancer.

Key Points: 
  • "Data from this trial will supplement data generated through our ongoing Phase 2 EVANGELINE trial, which is investigating (Z)-endoxifen as a neoadjuvant treatment for premenopausal women with ER+ / HER2- breast cancer.
  • The Karisma-Endoxifen trial is a randomized, double-blind, placebo-controlled efficacy study of oral (Z)–endoxifen in premenopausal women with measurable breast density.
  • Atossa will supply (Z)-endoxifen and provide financial support to Quantum Leap for this study.
  • Quantum Leap, as sponsor, will provide the clinical sites and clinical expertise.

Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial

Retrieved on: 
Tuesday, March 21, 2023
FNIH, University, Axis, Exemestane, Ki-67, Neoplasm, University of California, San Francisco, Clinical trial, Goserelin, MBD, Cancer, Woman, Hypothalamic–pituitary–gonadal axis, EOP, Bangladesh Technical Education Board, Atossa, Biomarker, Incidence, SERM, Quantum Leap, Patient, Risk, SAN, Enzyme inhibitor, Disease, Growth, Mortality, ESD, Therapy, Recurrence, Regulation of tobacco by the U.S. Food and Drug Administration, Tamoxifen, Food, ER, Breast cancer, Pharmaceutical industry, Birth control

“Data from this trial will supplement data generated through our ongoing Phase 2 EVANGELINE trial, which is investigating (Z)-endoxifen as a neoadjuvant treatment for premenopausal women with ER+ / HER2- breast cancer.

Key Points: 
  • “Data from this trial will supplement data generated through our ongoing Phase 2 EVANGELINE trial, which is investigating (Z)-endoxifen as a neoadjuvant treatment for premenopausal women with ER+ / HER2- breast cancer.
  • The Karisma-Endoxifen trial is a randomized, double-blind, placebo-controlled efficacy study of oral (Z)-endoxifen in premenopausal women with measurable breast density.
  • Atossa will supply (Z)-endoxifen and provide financial support to Quantum Leap for this study.
  • Quantum Leap, as sponsor, will provide the clinical sites and clinical expertise.

Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer

Retrieved on: 
Thursday, February 23, 2023
MBD, Breast cancer, Therapy, Goserelin, Cancer, Disease, Mortality, ESD, Risk, Ki-67, Exemestane, Patient, OFS, Growth, Breast, ER, Tamoxifen, Era, Cell proliferation, SERM, Woman, Incidence, Pharmaceutical industry, Birth control, Atossa

The study is expected to enroll approximately 175 patients at up to 25 sites across the United States.

Key Points: 
  • The study is expected to enroll approximately 175 patients at up to 25 sites across the United States.
  • (Z)-endoxifen administered as monotherapy may also obviate the need for OFS in premenopausal women and potentially reduce breast cancer cell proliferation.
  • The Company has an ongoing Phase 2 trial focused on reducing mammographic breast density (MBD) in healthy, premenopausal women.
  • Studies have also shown that women with MBD have an increased risk of developing breast cancer and that the higher the MBD, the higher the incidence of breast cancer.